{"name":"Graceway Pharmaceuticals, LLC","slug":"graceway-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aldara (imiquimod) cream, 5%","genericName":"Aldara (imiquimod) cream, 5%","slug":"aldara-imiquimod-cream-5","indication":"Actinic keratosis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GW05","genericName":"GW05","slug":"gw05","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Aldara (imiquimod) cream, 5%","genericName":"Aldara (imiquimod) cream, 5%","slug":"aldara-imiquimod-cream-5","phase":"marketed","mechanism":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.","indications":["Actinic keratosis","Basal cell carcinoma (superficial and nodular)","Genital warts (external)"],"catalyst":""},{"name":"GW05","genericName":"GW05","slug":"gw05","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNTlNUMDVON0lvSzhreTBCd04xVzFyRk5rZ2VKYUxxWTA1YWpkQU8yS1FNakotc3B5MkkybUdhc2s2XzNtR2FFWndOaHZFb0NMbzNRbUoteVEyV0hUTjdwZ3BmN3dwUzAxVUdWck5JOWNCMWdBWEs3RUNFUjlwVkVGenZ0Sk5SanR6SkRLaDZhdU9zNEtHR3c?oc=5","date":"2026-04-06","type":"earnings","source":"openPR.com","summary":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight - openPR.com","headline":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1ZRUhVcVkwM0dvbG1ya2hvRXRFU1pKcVBxa01tM3FBUWY3b0N4Uld2MEhRY3NtaC03MkFtNk9yNktvSXpEeV9fNDJmR3BOQ1l2X2E2YVBR?oc=5","date":"2015-08-26","type":"pipeline","source":"MarketBeat","summary":"Medicis Pharmaceutical (MRX) Stock Price, News & Analysis $MRX - MarketBeat","headline":"Medicis Pharmaceutical (MRX) Stock Price, News & Analysis $MRX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPbF9VWjhzZ2M4RVM0S1ZvTkJOb1UwSjNORDAtWHVHYlJENkl1WldYTDJZMGs0aktBNmtQejI3TG9BVzFZQU1SZ3pZRkFaSVZYQlFCRmxIZDM5X2tVa1ZCbTVBT0hzZVZBYVNnaU9ZcEQ5ZHVVS3ItaFhTUEJwOGZmMVRsSTV4bzJjWkt3RVVIYVA3cHd4cDFCM3M1YUMzZVN4NUtxblJfWUU1czZmRC1xeW1KRFlhdWxvdVkzUnNjQ2h2dWNzR2JVdkN0ZUtkZUVNaEVRQkhYcHkxZXhFdjdiUndsTDNHdUs0?oc=5","date":"2010-03-31","type":"regulatory","source":"BioSpace","summary":"FDA Approves Graceway Pharmaceuticals, LLC's Zyclara(TM)(imiquimod) Cream, 3.75% for Common Skin Pre-Cancer, Actinic Keratoses - BioSpace","headline":"FDA Approves Graceway Pharmaceuticals, LLC's Zyclara(TM)(imiquimod) Cream, 3.75% for Common Skin Pre-Cancer, Actinic Ker","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}